Any-grade serious TEAEs were reported in 18% of patients in the cemiplimab arm vs 9% of those in the placebo arm. Immune-mediated AEs were more common in the cemiplimab arm (23% any grade; 7% grade ≥ 3) than in the placebo arm (6% any grade; 0% grade ≥ 3). Rischin emphasized that the safety profile of adjuvant cemiplimab was consistent with what has been observed with other anti–PD-1 monotherapies and with cemiplimab in the advanced setting. Importantly, he noted that this trial represents the first to demonstrate in a statistically significant and clinically meaningful manner that adjuvant cemiplimab can improve outcomes in patients with high-risk CSCC following surgery. Rischin concluded that these findings support adjuvant cemiplimab as a potential new standard-of-care option for this population, offering patients and oncologists an evidence-based approach to reducing recurrence risk without introducing new safety concerns.